Drugs / Drospirenon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT02525276 | Aug 2015 → Aug 2018 | metabolic syndrome X | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06689150 Comparator | Aug 2023 → Aug 2024 | — | Al-Azhar University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Drospirenon | “Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.
Including:
Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat” NCT02525276 ↗1“About 100 women took Drospirenon (drospinetta) tab every day 24 and 4 placipo tablets for four days” NCT06689150 ↗ |
| Known as | drospinetta | “About 100 women took Drospirenon (drospinetta) tab every day 24 and 4 placipo tablets for four days” NCT06689150 ↗ |
| Route | Oral | “Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.” NCT02525276 ↗ |
| Route | Other | “Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.” NCT02525276 ↗ |